FI952170A0 - Stabilt preparat innehållande ett koagulationsbefrämjande aktivt ämne för behandling av blodkoagulationssjukdomar - Google Patents

Stabilt preparat innehållande ett koagulationsbefrämjande aktivt ämne för behandling av blodkoagulationssjukdomar

Info

Publication number
FI952170A0
FI952170A0 FI952170A FI952170A FI952170A0 FI 952170 A0 FI952170 A0 FI 952170A0 FI 952170 A FI952170 A FI 952170A FI 952170 A FI952170 A FI 952170A FI 952170 A0 FI952170 A0 FI 952170A0
Authority
FI
Finland
Prior art keywords
coagulation
blood
treatment
active substance
stable preparation
Prior art date
Application number
FI952170A
Other languages
English (en)
Finnish (fi)
Other versions
FI952170A (sv
Inventor
Johann Eibl
Hans Peter Schwarz
Juergen Siekmann
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI952170A0 publication Critical patent/FI952170A0/sv
Publication of FI952170A publication Critical patent/FI952170A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI952170A 1994-05-06 1995-05-05 Stabilt preparat innehållande ett koagulationsbefrämjande aktivt ämne för behandling av blodkoagulationssjukdomar FI952170A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4416180A DE4416180C2 (de) 1994-05-06 1994-05-06 Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats

Publications (2)

Publication Number Publication Date
FI952170A0 true FI952170A0 (sv) 1995-05-05
FI952170A FI952170A (sv) 1995-11-07

Family

ID=6517576

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952170A FI952170A (sv) 1994-05-06 1995-05-05 Stabilt preparat innehållande ett koagulationsbefrämjande aktivt ämne för behandling av blodkoagulationssjukdomar

Country Status (7)

Country Link
EP (1) EP0680763A3 (sv)
JP (1) JPH0840928A (sv)
AT (1) ATA77095A (sv)
CA (1) CA2148672A1 (sv)
DE (1) DE4416180C2 (sv)
FI (1) FI952170A (sv)
NO (1) NO951762L (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AU4709399A (en) * 1998-06-23 2000-01-10 Victor J. Marder Phospholipid vesicle-tissue factor complex preparations and methods of making and using same
US7056529B2 (en) * 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
CA2660310C (en) 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP3253870B1 (en) 2015-02-06 2021-06-23 Guangzhou Bioseal Biotech Co., Ltd. Method for preparation of thrombin
WO2020080496A1 (ja) * 2018-10-17 2020-04-23 東レ株式会社 止血材

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
US4610880A (en) * 1983-06-27 1986-09-09 Queen's University At Kingston Composition for controlling hemophilia in mammals
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
WO1990003808A1 (en) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Heat treating liposomes
WO1991002532A2 (en) * 1989-08-14 1991-03-07 Queen's University At Kingston Method for stimulating fibrinolytic effect
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
AU7384994A (en) * 1993-08-06 1995-02-28 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen

Also Published As

Publication number Publication date
ATA77095A (de) 2002-04-15
NO951762L (no) 1995-11-07
JPH0840928A (ja) 1996-02-13
NO951762D0 (no) 1995-05-05
CA2148672A1 (en) 1995-11-07
EP0680763A3 (en) 1998-01-28
DE4416180A1 (de) 1995-11-09
DE4416180C2 (de) 1997-08-14
FI952170A (sv) 1995-11-07
EP0680763A2 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
FI952169A0 (sv) Stabilt preparat för behandling av koagulationsstörningar av blodet
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
DE69807634T2 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NO20001754L (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
IT8868118A0 (it) Composizione e procedimento per il trattamento e la cura dei capelli
DE69620691T2 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DE69534632D1 (de) Clorimazole metabolite in den behandlung vom sichelzellanämie
KR890701094A (ko) 활성성분의 피부조직 전이흡수를 보장하는 약제학적 제제형 및 그 조제방법
FI952170A0 (sv) Stabilt preparat innehållande ett koagulationsbefrämjande aktivt ämne för behandling av blodkoagulationssjukdomar
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
KR960702315A (ko) 혈관 차단 치료에서의 헤모글로빈의 치료적 용도 (Therapeutic Use of Hemoglobin in the Treatment of Blood Vessel Blockage)
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE69822276T2 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE69813354T2 (de) Mittel zur Behandlung von Herzkrankheiten